Corporate | 13 March 2015 09:03
|
HAEMATO AG / Key word(s): Preliminary Results/Dividend
2014: Preliminary IFRS results, sales growth of 16 % to EUR 202.67 million, annual net income of EUR 6.98 million; confirmation of dividend policy In 2014 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 202.67 million (previous year: EUR 174.6 million) and profit of EUR 6.98 million (previous year: EUR 8.38 million; thereof non-recurring profit from sales of subsidiaries: EUR 2.64 million). “HAEMATO is investing in the expansion of sales activities as well as the production and storage capacities to achieve further growth. The earnings situation permits me to propose a dividend at the Annual General Shareholders’ Meeting, unchanged from the previous year of 30 Cent”, says Dr. Christian Pahl, Member of the Management Board of HAEMATO AG. About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. The company is listed on the Frankfurt Stock Exchange in the Entry Standard (Open Market).
Key figures for the share of HAEMATO AG:
Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de 2015-03-13 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| 332905 2015-03-13 |